Early and marked benefit with GPi DBS for Lubag syndrome presenting with rapidly progressive life-threatening dystonia.
Martinez-Torres
Irene
I
Limousin
Patricia
P
Tisch
Steve
S
Page
Rupert
R
Pinto
Ashwin
A
Foltynie
Thomas
T
Bhatia
Kailash P
KP
Hariz
Marwan I
MI
Zrinzo
Ludvic
L
D000328:Adult; D001764:Blepharospasm / Q000188:drug therapy / Q000209:etiology; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D046690:Deep Brain Stimulation; D018450:Disease Progression; D005808:Genes, Recessive; D040181:Genetic Diseases, X-Linked / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D005917:Globus Pallidus / Q000503:physiopathology*; D051548:Histone Acetyltransferases; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D020125:Mutation, Missense; D020734:Parkinsonian Disorders / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D012720:Severity of Illness Index; D035381:TATA-Binding Protein Associated Factors / Q000235:genetics*; D035362:Transcription Factor TFIID / Q000235:genetics*
D035381:TATA-Binding Protein Associated Factors; D035362:Transcription Factor TFIID; D051548:Histone Acetyltransferases; C069001:TATA-binding protein associated factor 250 kDa; D019274:Botulinum Toxins, Type A